What is CytomX Therapeutics's R&D?

CytomX Therapeutics (CTMX) reported R&D of $19.24M in Q1 2026.

How has CytomX Therapeutics's R&D changed year-over-year?

CytomX Therapeutics's R&D increased by 2.0% year-over-year, from $18.87M to $19.24M.

What is the long-term trend for CytomX Therapeutics's R&D?

Over 4 years (2021 to 2025), CytomX Therapeutics's R&D has grown at a -11.9% compound annual growth rate (CAGR), from $114.19M to $68.73M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

CytomX Therapeutics CTMX R&D

R&D at other companies

AmgenAMGN

$1.72B+15.7%

Janux TherapeuticsJANX

$26.81M+7.0%

Allogene TherapeuticsALLO

$32M-36.2%

Vor BiopharmaVOR

$17.6M-34.1%

Design Therapeutics, Inc.DSGN

$14.38M-6.5%

ImmunomeIMNM

$46.38M+25.8%

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's R&D?: CytomX Therapeutics (CTMX) reported R&D of $19.24M in Q1 2026.
How has CytomX Therapeutics's R&D changed year-over-year?: CytomX Therapeutics's R&D increased by 2.0% year-over-year, from $18.87M to $19.24M.
What is the long-term trend for CytomX Therapeutics's R&D?: Over 4 years (2021 to 2025), CytomX Therapeutics's R&D has grown at a -11.9% compound annual growth rate (CAGR), from $114.19M to $68.73M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.